{"url":"https://whatshealthyandwhy.com/akkermansia-muciniphila/gut-barrier-and-metabolic-health","path":"/akkermansia-muciniphila/gut-barrier-and-metabolic-health","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/akkermansia-muciniphila/gut-barrier-and-metabolic-health.json","markdown":"https://whatshealthyandwhy.com/akkermansia-muciniphila/gut-barrier-and-metabolic-health.md"},"topic":{"slug":"akkermansia-muciniphila","name":"Akkermansia Muciniphila","url":"https://whatshealthyandwhy.com/akkermansia-muciniphila"},"slug":"gut-barrier-and-metabolic-health","order":1,"title":"Gut Barrier and Metabolic Health","question":"Does Akkermansia muciniphila improve gut barrier and metabolic health?","answer":"Pasteurized Akkermansia supplements may improve insulin sensitivity and cholesterol in overweight adults, but this rests on one 12-week trial of 32 people.","description":"How Akkermansia muciniphila, a mucus-layer bacterium, protects the gut barrier and supports metabolic health","confidence":2,"confidenceNote":"One randomized pilot trial (32 completers, 12 weeks), one observational study of 49 people, and a systematic review of fifteen human and animal studies that calls for further clinical trials.","evidenceSummary":{"rctCount":1,"observationalCount":1,"metaAnalysisCount":1,"totalParticipants":"~90","replicated":false,"newestStudyYear":2021},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Supplements & Vitamins","subcategorySlug":"supplements","url":"https://whatshealthyandwhy.com/explore/good-for-you/supplements"},"actions":["Eat polyphenol-rich foods such as pomegranate, cranberry, green tea, dark grape skins and cacao, which increased Akkermansia in animal and human studies.","Include prebiotic fiber foods such as chicory root, garlic, leeks and apples; a 12–14 hour overnight fast may also help.","If supplementing, the trial used pasteurized Akkermansia at 10 billion bacteria a day for 12 weeks [3]."],"cautions":["Only one 12-week human trial has tested supplements, with no serious adverse events [3]; further clinical trials are needed to verify the benefits [5].","Not a replacement for medical care if you have insulin resistance or type 2 diabetes."],"simpleText":"Akkermansia muciniphila is a bacterium that lives in the mucus layer lining your gut — and its abundance is one of the strongest microbiome markers of metabolic health. People with obesity, type 2 diabetes, and metabolic syndrome consistently have lower levels of it. Restoring this bacterium — through diet, fasting, or supplementation — has been shown in human trials to improve insulin sensitivity, reduce cholesterol, and strengthen the gut barrier [3].","mediumText":"A Bacterium That Lives in Your Gut Lining\n\nUnlike most gut bacteria that live in the intestinal space, Akkermansia muciniphila (A. muciniphila) makes its home in the mucus layer that coats the gut wall. It belongs to the phylum Verrucomicrobia and makes up roughly 1–4% of gut bacteria in healthy adults. It is one of the most studied bacteria in microbiome research because its presence so strongly correlates with health — and its absence with disease [1].\n\nA. muciniphila feeds on mucin, the protein that makes up your gut's protective mucus layer. This might sound harmful, but the bacterium actually stimulates the gut to continuously regenerate that mucus, resulting in a thicker, more resilient barrier. A thicker mucus layer means pathogens and bacterial toxins have a harder time reaching the gut wall [1].\n\nHow It Protects Metabolic Health\n\nThe gut barrier serves as a gatekeeper between the microbial world in your intestines and your bloodstream. When this barrier weakens — a condition researchers call intestinal permeability or \"leaky gut\" — fragments of bacterial cell walls called lipopolysaccharides (LPS) can leak into circulation. This triggers chronic, low-grade inflammation throughout the body, a state called metabolic endotoxemia that is closely linked to insulin resistance, fatty liver, and cardiovascular disease.\n\nA. muciniphila counters this through several mechanisms:\n\nTight junction reinforcement. The bacterium upregulates proteins like claudin-3 that physically seal the gaps between gut wall cells, reducing LPS translocation into the bloodstream [1].\n\nThe Amuc_1100 protein. Researchers identified a specific outer membrane protein from A. muciniphila called Amuc_1100. This protein interacts with Toll-like receptor 2 (TLR2) on gut cells, activating immune pathways that reduce gut permeability and systemic inflammation. In mouse studies, Amuc_1100 alone reproduced the metabolic benefits of the whole bacterium [2].\n\nEndocannabinoid regulation. A. muciniphila administration increases intestinal levels of endocannabinoids — specifically 2-arachidonoylglycerol (2-AG) and N-palmitoylethanolamide (PEA). These compounds regulate gut barrier integrity, inflammation, and the release of gut hormones involved in appetite control [1].\n\nPropionate production. A. muciniphila generates propionate, a short-chain fatty acid that signals to the liver and brain to regulate glucose production and appetite.\n\nThe Pasteurized Form May Work Better\n\nOne unexpected finding from research is that pasteurized (heat-killed) A. muciniphila often outperforms the live bacterium. This is because the Amuc_1100 protein is heat-stable — it survives pasteurization and remains active in the gut. Live bacteria may not colonize efficiently in an already-disrupted microbiome, while the pasteurized form delivers the active protein directly [2].\n\nHuman Trial Results\n\nThe landmark human trial by Depommier et al. (2019) tested both live and pasteurized A. muciniphila against placebo in 32 overweight, insulin-resistant adults over three months. Compared to placebo, the pasteurized form produced [3]:\n\n- +28.6% improvement in insulin sensitivity\n- -34% reduction in fasting insulin levels\n- -8.7% reduction in total cholesterol\n- Modest reductions in body weight, fat mass, and waist circumference\n\nNo serious adverse events were recorded, confirming its safety profile.\n\nWhat Depletes Akkermansia\n\nA. muciniphila is sensitive to disruption. Factors that reduce its abundance include:\n\n- Antibiotic use (especially broad-spectrum antibiotics)\n- High-fat, low-fiber diets\n- Aging (levels naturally decline with age)\n- Obesity and type 2 diabetes (lower levels are a feature, not just a marker)\n- Chronic stress and sleep disruption\n\nHow to Raise Your Akkermansia Levels Naturally\n\nSeveral dietary and lifestyle strategies have been shown to support A. muciniphila abundance:\n\nPolyphenol-rich foods. Pomegranate extract, cranberry, green tea catechins, dark grape skins, and cacao polyphenols all increase A. muciniphila in animal and human studies. Polyphenols are poorly absorbed in the small intestine, arriving intact in the colon where they selectively feed this bacterium.\n\nIntermittent fasting. Periods without food allow the mucus layer to regenerate undisturbed and appear to favor A. muciniphila proliferation. Even a 12–14 hour overnight fast may help.\n\nPrebiotic fibers. Foods containing inulin, FOS (fructooligosaccharides), and pectin — including chicory root, Jerusalem artichokes, garlic, leeks, and apples — support the conditions in which A. muciniphila thrives.\n\nOmega-3 fatty acids. Dietary fish oil has been shown to increase A. muciniphila abundance in animal models, possibly by reducing the gut inflammation that suppresses it.\n\nDirect supplementation. Pasteurized A. muciniphila supplements are commercially available. The clinically tested dose in the Depommier trial was 10^10 colony-forming units per day.\n\nSee our probiotics page for broader context on cultivating a healthy microbiome, and our leaky gut page for more on gut barrier repair.","deepText":"Evidence Review\n\nThe Landmark Mouse Study: Everard et al. (2013)\n\nEverard and colleagues published the foundational A. muciniphila paper in PNAS in 2013, establishing a causal role for this bacterium in metabolic health [1]. Using high-fat diet-induced obese mice, they showed that A. muciniphila abundance was dramatically reduced in obese animals compared to lean controls. Prebiotic feeding (oligofructose) restored A. muciniphila to normal levels and this restoration correlated with improved metabolic markers.\n\nCritically, when they administered A. muciniphila directly to high-fat diet mice, it reversed several features of metabolic syndrome: fat mass gain was reduced, metabolic endotoxemia decreased (lower circulating LPS), adipose tissue inflammation was blunted, and insulin resistance improved. Mechanistically, A. muciniphila increased intestinal endocannabinoids — specifically 2-AG and palmitoylethanolamide — which the authors linked to tighter barrier junctions and reduced inflammation.\n\nAn important finding was that heat-killed A. muciniphila failed to produce these benefits in this study, suggesting that (in this model) viable bacteria were required. This would later be complicated by the Plovier findings.\n\nThe Amuc_1100 Discovery: Plovier et al. (2017)\n\nPlovier et al. (2017) resolved a key mechanistic question in Nature Medicine [2]. They investigated why pasteurized A. muciniphila worked better than expected, identifying Amuc_1100 as the responsible protein. This outer membrane protein survives pasteurization temperatures and activates TLR2 on intestinal epithelial cells.\n\nIn high-fat diet mice, Amuc_1100 alone reduced fat mass development, improved insulin tolerance, reduced LPS levels, and restored gut barrier integrity, matching the effects of the whole pasteurized bacterium. Structural analysis confirmed that Amuc_1100 forms a pilus-like surface appendage involved in mucin interaction, and its immunostimulatory effects via TLR2 appear central to its benefits.\n\nThis study also confirmed that pasteurized A. muciniphila performed comparably or better than live bacteria in improving metabolism — an important finding for supplement development, since pasteurized preparations are more stable and easier to manufacture.\n\nPre-Clinical Human Evidence: Dao et al. (2016)\n\nDao et al. examined the clinical relevance of A. muciniphila in 49 obese adults enrolled in a dietary intervention (caloric restriction) in France [4]. They found that participants who had higher baseline A. muciniphila had a healthier metabolic status at the start of the trial, including better insulin sensitivity, lower adiposity, and less metabolic endotoxemia. More importantly, those with higher baseline abundance experienced greater metabolic improvements during the dietary intervention, suggesting that A. muciniphila may amplify the benefits of healthy dietary changes.\n\nThis observational finding provided strong motivation for the supplementation trials that followed.\n\nThe Human Supplementation Trial: Depommier et al. (2019)\n\nDepommier et al. conducted a randomized, double-blind, placebo-controlled pilot trial published in Nature Medicine [3], the first to test A. muciniphila supplementation in humans. Forty overweight or obese insulin-resistant volunteers were enrolled; 32 completed the 12-week trial. Participants were randomized to: placebo, live A. muciniphila (10^10 bacteria/day), or pasteurized A. muciniphila (10^10 bacteria/day).\n\nKey outcomes for the pasteurized group versus placebo:\n- Insulin sensitivity (HOMA-IR): +28.62% ± 7.02% (p = 0.002)\n- Fasting insulinemia: -34.08% ± 7.12% (p = 0.006)\n- Total plasma cholesterol: -8.68% ± 2.38% (p = 0.02)\n- Body weight, fat mass, and hip circumference all showed modest non-significant reductions vs. baseline\n- No statistically significant effects in the live group on the primary endpoint\n\nSafety was confirmed with no serious adverse events and no significant changes in inflammatory markers or standard blood chemistry. A. muciniphila was detectable in stool during the trial, suggesting at least transient colonization.\n\nThe trial was small (n=32 completers) and not powered to detect changes in body weight as a primary endpoint. Nevertheless, the insulin sensitivity result was striking and has driven commercial development of pasteurized A. muciniphila products.\n\nSystematic Review: Roshanravan et al. (2021)\n\nA comprehensive systematic review evaluated the effectiveness and mechanisms of action of A. muciniphila supplementation in the management of obesity [5]. Searching MEDLINE, PubMed, Scopus, Web of Science, and Google Scholar through March 2020, it included fifteen studies, covering both human and animal (rodent) models. Its findings support A. muciniphila supplementation as a novel therapeutic approach for the management of obesity and the metabolic complications associated with obesity.\n\nThe review noted that future clinical trials are warranted to verify these outcomes.\n\nStrength of Evidence\n\nThe evidence base for A. muciniphila is unusually strong for a gut microbiome topic: the mechanistic pathway (mucus layer → barrier function → metabolic endotoxemia → insulin resistance) is biologically coherent, replicated across multiple animal models, and now supported by a proof-of-concept human RCT. The identification of Amuc_1100 as a specific active protein provides a level of mechanistic clarity that most probiotic research lacks. However, the human evidence remains limited to a single small trial, and confirmation in larger independent studies is needed before firm clinical recommendations can be made.","deepTruncated":false,"references":[{"id":"1","title":"Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity","authors":"Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD","year":2013,"journal":"Proceedings of the National Academy of Sciences","pmid":"23671105","url":"https://pubmed.ncbi.nlm.nih.gov/23671105/"},{"id":"2","title":"A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice","authors":"Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD","year":2017,"journal":"Nature Medicine","pmid":"27892954","url":"https://pubmed.ncbi.nlm.nih.gov/27892954/"},{"id":"3","title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","authors":"Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD","year":2019,"journal":"Nature Medicine","pmid":"31263284","url":"https://pubmed.ncbi.nlm.nih.gov/31263284/"},{"id":"4","title":"Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology","authors":"Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L, Dumas ME, Rizkalla SW, Doré J, Cani PD, Clément K","year":2016,"journal":"Gut","pmid":"26100928","url":"https://pubmed.ncbi.nlm.nih.gov/26100928/"},{"id":"5","title":"A comprehensive systematic review of the effectiveness of Akkermansia muciniphila, a member of the gut microbiome, for the management of obesity and associated metabolic disorders","authors":"Roshanravan N, Bastani S, Tutunchi H, Kafil B, Nikpayam O, Mesri Alamdari N, Hadi A, Sotoudeh S, Ghaffari S, Ostadrahimi A","year":2021,"journal":"Archives of Physiology and Biochemistry","pmid":"33449810","url":"https://pubmed.ncbi.nlm.nih.gov/33449810/"}],"wordCount":1543,"source":{"path":"src/content/topics/akkermansia-muciniphila/gut-barrier-and-metabolic-health.md"},"citeAs":"“Does Akkermansia muciniphila improve gut barrier and metabolic health?.” What's Healthy and Why. https://whatshealthyandwhy.com/akkermansia-muciniphila/gut-barrier-and-metabolic-health","notice":"General information backed by peer-reviewed research, not medical advice."}